The US Food and Drug Administration’s (FDA) Oncologic Drugs Advisory Committee has recommended approval of the first biosimilar version of trastuzumab, a breast cancer-fighting monoclonal antibody.
Start a subscription today to access the LSIPR website.
To access the full archive, digital magazines and special reports you will need to take out a paid subscription.
If you have already subscribed please login.
If you have any technical issues please email tech support.
For access to the complete website, archive, and to receive print publications, choose '12 MONTH SUBSCRIPTION'. For a free, two-week trial with full access, select ‘TWO WEEK FREE TRIAL’.
FDA, trastuzumab, biosimilar, Mylan, Biocon, Herceptin, US Food and Drug Ad-ministration, cancer
